FindTrial
Sign In

Transvaginal three-dimensional contrast-enhanced ultrasound in the diagnosis of endometrial carcinoma of applied research

Transvaginal three-dimensional contrast-enhanced ultrasound in the diagnosis of endometrial carcinom

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDT-14004905
Enrollment
Unknown
Registered
2014-07-02
Start date
2013-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial Carcinoma

Interventions

Gold Standard:
Index test:

Sponsors

the First of Affiliated Hospital of Xinjiang Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
23 Years to 78 Years

Inclusion criteria

Inclusion criteria: series patients with endometrial carcinoma found by abdominal or transvaginal ultrasound examination

Exclusion criteria

Exclusion criteria: patients with renal serious insufficiency; patients with an allergy to Sulphur Hexafluoride or composition of SonoVue, and deficiency in catalase; patients with right to left shunt heart diseases, Severe pulmonary hypertension, fails to control hypertension and adult respiratory distress syndrome; pregnant and lactating women,minors aged below 18.

Design outcomes

Primary

MeasureTime frame
perfusion patterns of contrast-enhanced ultrasound;vascular pattern of three-dimensional contrast-en;perfusion intensity of contrast-enhanced ultrasoun;Time-intensity curve;Perfusion uniformity of contrast-enhanced ultrasou;—

Countries

China

Contacts

Public ContactHong Xiang
xianghong65@126.com+86 0991-4362158

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026